Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab in Idiopathic Pulmonary Fibrosis
NCT06132256Phase 2Active, not recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF), sponsored by Syndax Pharmaceuticals. Started Dec 2023; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06132256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132256.